Digibind

Digibind

 [dij´ĭ-bīnd]
trademark for a preparation of digoxin immune Fab (ovine), an antidote for digoxin or digitoxin overdose.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.
A therapeutic agent consisting of antigen binding fragments (Fab) derived from antidigoxin antibodies raised in sheep, which have a molecular weight of 46kD. It is used to manage digoxin overdose, and has been used successfully for digitoxin overdose
Adverse effects Rare, in patients with a history of allergy, especially to antibiotics; low cardiac output states and congestive heart failure may be exacerbated by withdrawal of the inotropic effects of digitalis. Hypokalemia may occur from re-activation of (sodium, potassium) ATPase
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
Upon the attending physician's arrival to the PICU a nurse documented that he was notified of the digoxin administration error and asked if Digibind should be given.
Digibind, an antidote for digoxin toxicity was administered.
Digoxin toxicity can be rapidly and safely reversed by administration of anti-dioxin immune fragments (Fab) such as DIGIBIND [R], which has been available in the US since 1986.
Benjamin was transferred to the Birmingham hospital to receive the antidote Digibind. During the journey he was continually resuscitated.
The companies cite reports from the Food and Drug Administration that DigiFab and GlaxoSmithKline PLC's Digibind have been reduced to limited inventories.
Antibody-targeted imaging reagents Mouse 23 Rat 24 Antibody-targeted drugs Mouse 23 Rat 24 Anti-thymocyte globulin Horse 25 Rabbit 26 Anti-snake venom Horse 27 Calcitonin Salmon 28 Digibind (anti-digoxin Fab) Sheep 29 Factor VIII Pig 30 Insulin Pig 31 Vaccines Rabbit 32 Chicken 33 Patent medicines Rabbit 34 Table 2.
Nonetheless, one can agree that results from the Stratus II and AxSYM may be suitable for monitoring the course of Digibind treatment.
Green, entitled "Serum digoxin in the presence of Digibind: determination of digoxin by the Abbott AxSYM and Baxter Stratus II immunoassays by direct analysis without pretreatment of serum samples" (Clin Chem 1998;44:1947-50), the concentration of Digibind given in parentheses in the sentence at the bottom of the second column on page 1948 is incorrect.
Digibind [R] (Glaxo Wellcome) is the most common brand of anti-digoxin Fab fragments used in the United States and worldwide.
Digibind [R] (Digoxin Immune FAB) given to patients who are digitoxic can cause substantial interferences in tracking therapeutic concentrations of digoxin depending on the type of assay methodology used.
Specimens from patients treated with digoxin antidote (e.g., Digibind) give misleading values for digoxin concentrations by most immunoassays tested to date (101).
Also in this case, the intravenous administration of the Fab fragment of antidigoxin antibodies (Digibind) determined a significant reduction in her blood pressure.